Trial reportArchives of ophthalmology (Chicago, Ill. : 1960)2010
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.
Trial report in Archives of ophthalmology (Chicago, Ill. : 1960), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00542178. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study
Open the trial in the graphWho cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Blood pressure control for diabetic retinopathy.The Cochrane database of systematic reviews · 2023Pooled it
- Blood pressure control for diabetic retinopathy.The Cochrane database of systematic reviews · 2015Pooled it
- Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study.American journal of ophthalmology · 2018Trial
- Choroidal Thickening Induced by Pioglitazone in Diabetic Patients.Korean journal of ophthalmology : KJO · 2024Article
- Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Review
- Potential therapeutic effects of peroxisome proliferator-activated receptors on corneal diseases.Experimental biology and medicine (Maywood, N.J.) · 2024Review
- Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.JAMA network open · 2023Article
- Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study.Scientific reports · 2023Article
- The effect of insulin on response to intravitreal anti-VEGF injection in diabetic macular edema in type 2 diabetes mellitus.BMC ophthalmology · 2022Article
- The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.Experimental eye research · 2021Review
- The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathy-A Review.Journal of clinical medicine · 2021Review
- New anti-hyperglycaemic agents for type 2 diabetes and their effects on diabetic retinopathy.Eye (London, England) · 2019Review
- Diabetic macular edema: Evidence-based management.Indian journal of ophthalmology · 2018Review
- Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?Current diabetes reports · 2017Review
- The Role of Systemic Risk Factors in Diabetic Retinopathy.Current ophthalmology reports · 2016Review
- Sight-threatening diabetic eye disease: an update and review of the literature.The British journal of general practice : the journal of the Royal College of General Practitioners · 2014Review
- Article
- Evidence underlying the clinical management of diabetic macular oedema.Clinical medicine (London, England) · 2013Review
- Personalizing guidelines for diabetes management: twilight or dawn of the expert?BMC medicine · 2013Review
- Drug-induced macular edema.Drugs · 2013Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo assess the cross-sectional association of thiazolidinediones with diabetic macular edema (DME).
methodsThe cross-sectional association of DME and visual acuity with thiazolidinediones was examined by means of baseline fundus photographs and visual acuity measurements from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Visual acuity was assessed in 9690 participants in the ACCORD trial, and 3473 of these participants had fundus photographs that were centrally read in a standardized fashion by masked graders to assess DME and retinopathy from October 23, 2003, to March 10, 2006.
resultsAmong the subsample, 695 (20.0%) people had used thiazolidinediones, whereas 217 (6.2%) people had DME. Thiazolidinedione use was not associated with DME in unadjusted (odds ratio [OR], 1.01; 95% confidence interval [CI], 0.71-1.44; P = .95) and adjusted (OR, 0.97; 95% CI, 0.67-1.40; P = .86) analyses. Significant associations with DME were found for retinopathy severity (P < .001) and age (OR, 0.97; 95% CI, 0.952-0.997; P = .03) but not for hemoglobin A(1c) (P = .06), duration of diabetes (P = .65), sex (P = .72), and ethnicity (P = .20). Thiazolidinedione use was associated with slightly greater visual acuity (0.79 letter; 95% CI, 0.20-1.38; P = .009) of uncertain clinical significance.
conclusionsIn a cross-sectional analysis of data from the largest study to date, no association was observed between thiazolidinedione exposure and DME in patients with type 2 diabetes; however, we cannot exclude a modest protective or harmful association. Trial Registration clinicaltrials.gov Identifier: NCT00542178.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.